2. The composition of claim 1, wherein:
the anti-androgen is any one or combination of: cyproterone acetate, megestrol acetate, chlormadinone acetate, spironolactone, medrogestone, oxendolone, osaterone, bifluranol, finasteride, dutasteride, flutamide, bicalutamide, nilutamide, topilutamide, enzalutamide, apalutamide, dienogest, drospirenone, medrogestone, nomegestrol acetate, promegestone, trimegestone, ketoconazole, abiraterone acetate, seviteronel, aminoglutethimide, epristeride, alfaestradiol, isotretinoin, saw palmetto, darolutamide, galeterone, proxalutamide, triptorelin pamoate, allylestrenol, chlormadinone acetate, or degarelix.

3. The composition of claim 1, wherein the composition is formulated to facilitate administration of the composition topically to the skin, nasally, sub-lingually, orally, by injection, via inhalation, or ocular application.

4. The composition of claim 1, wherein the viral respiratory infection is any one or combination of coronavirus, influenza, influenza A, influenza B, SARS-CoV-1, SARS-CoV-2, MERS-CoV, or rhinovirus.

5. The composition of claim 1, wherein the anti-androgen is combined with any one or combination of an anti-inflammatory agent, an anti-bacterial agent, or aspartame.

6. The composition of claim 1, wherein the composition is formulated for use as a treatment of the viral respiratory infection, a therapy for the viral respiratory infection, a prophylactic for the viral respiratory infection, and/or a preventive measure for contracting the viral respiratory infection.

7. The composition of claim 6, wherein the composition is further formulated for use as a treatment for prostate cancer, castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer and/or benign prostatic hyperplasia.

8. A method of treating a patient having or suspected of having a viral respiratory infection, the method comprising:
administering a composition to the patient, the composition including any one or combination of:
an androgen receptor antagonists or anti-androgen;
an androgen synthesis inhibitor;
an agent that counters the effect of androgens;
a globulin (SHBG) stimulator;
an antigonadotropins;
a mineralocorticoid to suppress androgen production in the adrenal gland;
a glucocorticoid to suppress androgen production in the adrenal gland;
an insulin sensitizing medication; and
vaccine or an immunogen against androstenedione that reduces the level of testosterone or increases estrogen.

9. The method of claim 8, wherein:
the anti-androgen is any one or combination of: cyproterone acetate, megestrol acetate, chlormadinone acetate, spironolactone, medrogestone, oxendolone, osaterone, bifluranol, finasteride, dutasteride, flutamide, bicalutamide, nilutamide, topilutamide, enzalutamide, apalutamide, dienogest, drospirenone, medrogestone, nomegestrol acetate, promegestone, trimegestone, ketoconazole, abiraterone acetate, seviteronel, aminoglutethimide, epristeride, alfaestradiol, isotretinoin, saw palmetto, darolutamide, galeterone, proxalutamide, triptorelin pamoate, allylestrenol, chlormadinone acetate, or degarelix.

10. The method of claim 8, wherein the administration of the composition involves any one or combination of topical application to the skin, nasal application, sub-lingual application, oral application, via injection, via inhalation, or ocular application.

11. The method of claim 8, wherein the viral respiratory infection is any one or combination of coronavirus, influenza, influenza A, influenza B, SARS-CoV-1, SARS-CoV-2, MERS-CoV or rhinovirus.

12. The method of claim 8, wherein the composition is used as a treatment for the viral respiratory infection, a therapy for the viral respiratory infection, a prophylactic for the viral respiratory infection, and/or a preventive measure for contracting the viral respiratory infection.

13. The method of claim 8, wherein the treatment involves administering the composition as a treatment for the viral respiratory infection and/or a prophylactic for the viral respiratory infection before, during, and/or after the patient is first diagnosed with the viral respiratory infection and/or before, during, and/or after the patient is hospitalized due to the viral respiratory infection.

14. The method of claim 12, wherein the composition is further used as a treatment for prostate cancer, castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer and/or benign prostatic hyperplasia.

15. The method of claim 8, further comprising predicting anti-androgen treatment response via evaluation of genetic variation in the gene and/or promotor region of the androgen receptor (AR).

16. The method of claim 15, further comprising guiding selection of anti-androgen treatment and/or dosage selection of the selected anti-androgen treatment based on the predicted anti-androgen treatment response.

17. The method of claim 15, wherein predicting the anti-androgen treatment response involves measuring polymorphisms in the AR gene.

18. The method of claim 15, wherein:
the number of cytosine-adenine-guanine (CAG) repeats in the first exon of the AR gene, the number of guanine-guanine-(any nucleotide) (GGN) repeats in the first exon in the AR gene, and/or a ratio of CAG/GGN repeats is used as the genetic variant; and
a cut off value for the number of CAG repeats the first exon of AR gene is used to define a person with androgen sensitivity.

19. The method of claim 18, wherein the cut-off value for the number of CAG repeats the first exon of AR gene is between 10 and 30.

20. The method of claim 15, wherein variants in the promoter region of the AR are used as the genetic variant.

21. The method of claim 8, wherein the anti-androgen is combined with any one or combination of an anti-inflammatory agent, an anti-bacterial agent, or aspartame.

22. The method of claim 21, wherein the viral respiratory infection is SARS-CoV-2.

23. The method of claim 8, wherein administering the composition involves administering:
topical skin application of finasteride at 1-30% (w/w), oral finasteride at 0.01-30 mg, dutasteride at 0.1 mg/day to 3.0 mg/day, degarelix at 24 mg-720 mg, oral cannabidiol at 1-30/mg/Kg/day, oral flutamide at 75-2,